Literature DB >> 16572451

Antimuscarinic antibodies in primary Sjögren's syndrome reversibly inhibit the mechanism of fluid secretion by human submandibular salivary acinar cells.

L J Dawson1, J Stanbury, N Venn, B Hasdimir, S N Rogers, P M Smith.   

Abstract

OBJECTIVE: Sjögren's syndrome (SS) is an autoimmune condition affecting salivary glands, for which a clearly defined pathogenic autoantibody has yet to be identified. Autoantibodies that bind to the muscarinic M3 receptors (M3R), which regulate fluid secretion in salivary glands, have been proposed in this context. However, there are no previous data that directly show antisecretory activity. This study was undertaken to investigate and characterize the antisecretory activity of anti-M3R.
METHODS: Microfluorimetric Ca2+ imaging and patch clamp electrophysiologic techniques were used to measure the secretagogue-evoked increase in [Ca2+]i and consequent activation of Ca2+-dependent ion channels in individual mouse and human submandibular acinar cells. Together, these techniques form a sensitive bioassay that was used to determine whether IgG isolated from patients with primary SS and from control subjects has antisecretory activity.
RESULTS: IgG (2 mg/ml) from patients with primary SS reduced the carbachol-evoked increase in [Ca2+]i in both mouse and human acinar cells by approximately 50%. IgG from control subjects had no effect on the Ca2+ signal. Furthermore, the inhibitory action of primary SS patient IgG on the Ca2+ signal was acutely reversible. We repeated our observations using rabbit serum containing antibodies raised against the second extracellular loop of M3R and found an identical pattern of acutely reversible inhibition. Anti-M3R-positive serum had no effect on Ca2+-dependent ion channel activation evoked by the direct intracellular infusion of inositol 1,4,5-triphosphate.
CONCLUSION: These observations show for the first time that IgG from patients with primary SS contains autoantibodies capable of damaging saliva production and contributing to xerostomia. The unusual but not unprecedented acute reversibility of the effects of anti-M3 autoantibodies is the subject of further research.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16572451     DOI: 10.1002/art.21764

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  32 in total

1.  Candidate chromosome 1 disease susceptibility genes for Sjogren's syndrome xerostomia are narrowed by novel NOD.B10 congenic mice.

Authors:  Patricia K A Mongini; Jill M Kramer; Tomo-O Ishikawa; Harvey Herschman; Donna Esposito
Journal:  Clin Immunol       Date:  2014-03-29       Impact factor: 3.969

2.  Efficacy prediction of cevimeline in patients with Sjögren's syndrome.

Authors:  Hiroyuki Yamada; Yoichi Nakagawa; Ei Wakamatsu; Takayuki Sumida; Shigeo Yamachika; Yoshiaki Nomura; Kenji Mishima; Ichiro Saito
Journal:  Clin Rheumatol       Date:  2007-01-13       Impact factor: 2.980

Review 3.  Sjögren's syndrome accompanied with interstitial cystitis: a case report and review of the literature.

Authors:  Dongfeng Liang; Jinshan Lu; Aitao Guo
Journal:  Clin Rheumatol       Date:  2014-01-07       Impact factor: 2.980

4.  Activation of innate immunity accelerates sialoadenitis in a mouse model for Sjögren's syndrome-like disease.

Authors:  S-R Nandula; Y M Scindia; P Dey; H Bagavant; U S Deshmukh
Journal:  Oral Dis       Date:  2011-08-04       Impact factor: 3.511

Review 5.  Update on Pathogenesis of Sjogren's Syndrome.

Authors:  Pulukool Sandhya; Biji Theyilamannil Kurien; Debashish Danda; Robert Hal Scofield
Journal:  Curr Rheumatol Rev       Date:  2017

6.  New epitopes and function of anti-M3 muscarinic acetylcholine receptor antibodies in patients with Sjögren's syndrome.

Authors:  H Tsuboi; I Matsumoto; E Wakamatsu; Y Nakamura; M Iizuka; T Hayashi; D Goto; S Ito; T Sumida
Journal:  Clin Exp Immunol       Date:  2010-08-20       Impact factor: 4.330

7.  [Autoimmune sialadenitis].

Authors:  O Guntinas-Lichius; A Vissink; S Ihrler
Journal:  HNO       Date:  2010-03       Impact factor: 1.284

8.  [Sjögren's syndrome. Current aspects from a rheumatological point of view].

Authors:  C Tomiak; T Dörner
Journal:  Z Rheumatol       Date:  2006-10       Impact factor: 1.372

9.  Muscarinic type 3 receptor autoantibodies are associated with anti-SSA/Ro autoantibodies in Sjögren's syndrome.

Authors:  Jian Zuo; Adrienne E G Williams; Yun-Jong Park; Kevin Choi; Annie L Chan; Westley H Reeves; Michael R Bubb; Yun Jong Lee; Kyungpyo Park; Carol M Stewart; Seunghee Cha
Journal:  J Immunol Methods       Date:  2016-07-25       Impact factor: 2.303

10.  A novel luminescence-based method for the detection of functionally active antibodies to muscarinic acetylcholine receptors of the M3 type (mAchR3) in patients' sera.

Authors:  B Preuss; S Tunaru; J Henes; S Offermanns; R Klein
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.